Compare AbbVie Inc (ABBV) vs Akamai Technologies, Inc. (AKAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Akamai Technologies, Inc. — how do they compare? AbbVie Inc trades at $254.02 (market cap $449.91B), while Akamai Technologies, Inc. trades at $113.7 (market cap $16.63B). The key difference: AbbVie Inc is far larger — about 27.1× Akamai Technologies, Inc.'s market cap, and AbbVie Inc pays a 2.72% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | AKAM | |
|---|---|---|
Market Cap | $449.91B | $16.63B |
Sector | Health | Technology |
52-Week High | $261.07 | $161.14 |
52-Week Low | $184.85 | $70.53 |
Enterprise Value | $513.38B | $21.56B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.76, down 2.42% on the day, with strong technical momentum showing bullish moving averages despite overbought RSI readings. The company demonstrates solid fundamental performance with Q1 2026 earnings beating expectations at $2.65 EPS versus $2.59 expected, continuing a trend of quarterly beats. Revenue growth remains robust at $61.16 billion for 2025, supported by successful portfolio transition beyond Humira patent expiration.
AbbVie presents a compelling investment case with 68% analyst buy ratings and a $266.33 consensus target offering 4.5% upside. Key opportunities include Skyrizi and Rinvoq driving growth, while risks involve patent cliffs in the 2030s and high valuation multiples. The company's dividend aristocrat status and strong cash flow generation support continued shareholder returns.
Akamai Technologies (AKAM) trades at $114.37, up 1.06% on the day but down significantly from its 26-year high of $165.45 in May 2026. The stock faces a bearish technical signal despite recent earnings beats. Revenue growth has slowed to 5% annually, with net income margin declining from 14.47% in 2022 to 10.74% in 2025. The company continues strategic moves in cybersecurity, completing the LayerX acquisition and expanding its NVIDIA partnership for AI security.
While analyst consensus remains positive with a $170.20 price target, near-term headwinds include declining profitability, high valuation multiples, and competitive pressures. The stock's current pullback presents a potential entry point for long-term investors believing in its cybersecurity and cloud computing positioning, though execution risks and margin compression require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →
